Pei-Yin Tsai

Dr. Pei-Yin Tsai


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2023 in Journal of Infection and Public Health
Verified
Journal Article
Open access
CLChih-Wei Lin
Chih-Wei Lin
YLYu-Ling Liang
Yu-Ling Liang
MCMing-Ta Chuang
Ming-Ta Chuang
CTChun Han Tseng
Chun Han Tseng
PTPei-Yin Tsai
Pei-Yin Tsai
MSMei-Tsz Su
Mei-Tsz Su
Paxlovid is an oral drug composed of nirmatrelvir and ritonavir that has been demonstrated to be effective in decreasing the risk of severe coronavirus disease 2019 (COVID-19). Here, we report the use of paxlovid in pregnant women with COVID-19. Pregnant women attending a tertiary referral hospital in Taiwan from 29 April to 30 July 2022 were enrolled in the study. We compared baseline characteristics, clinical manifestations, and adverse events between paxlovid-treated women and those without paxlovid use. Maternal and neonatal outcomes were analysed in women who delivered during the study period. A total of 30 paxlovid-treated pregnant women and 55 women without paxlovid use were included in the analysis. The mean duration of COVID-19-associated symptoms in the paxlovid-treated women was shorter than that in the control group (10.10 days versus 15.59 days, p = 0.04). No severe adverse events due to paxlovid use were observed. Dysgeusia and diarrhoea were the most common adverse effects. Thirteen paxlovid-treated and 28 untreated women delivered during the study period. More pregnant women in the paxlovid group who delivered during the study period underwent caesarean delivery compared to the group without antiviral treatment (10 of 13 [76.92%] versus 12 of 28 [42.86%], p = 0.042), and insignificantly more newborns were born small for gestational age in the paxlovid group compared to the control group (3 of 13 [23.08%] versus 1 of 28 [3.57%], p = 0.086). Our study showed that paxlovid was effective and safe for pregnant women during the Omicron wave of the COVID-19 pandemic. A higher proportion of caesarean delivery rates was observed among paxlovid-treated women. Long-term follow-up of pregnant women exposed to paxlovid and their offspring is needed.

5 February 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
CCChia-Jung Chiang
Chia-Jung Chiang
WHWei-Lun Hsu
Wei-Lun Hsu
MSMeitsz Su
Meitsz Su
WKWen-Chien Ko
Wen-Chien Ko
KHKeng-fu Hsu
Keng-fu Hsu
PTPei-Yin Tsai
Pei-Yin Tsai
A pregnancy booster dose significantly reduces the risk and severity of COVID-19, and it is widely recommended. A prospective cohort study was conducted to compare the transplacental passage of maternal antibodies from vaccination or infection during three trimesters against both the vaccine-targeted Wuhan strain and the Omicron strain of SARS-CoV-2. Maternal–infant dyads from vaccinated mothers were collected between 6 June 2022 and 20 September 2022. We analyzed 38 maternal–infant dyads from mothers who had been infected with COVID-19 and 37 from mothers without any previous infection. Pregnant women who received their last COVID-19 vaccine dose in the third trimester exhibited the highest anti-spike protein antibody levels and neutralizing potency against both the Wuhan strain and Omicron BA.2 variant in their maternal and cord plasma. Both second- and third-trimester vaccination could lead to a higher level of neutralization against the Wuhan and Omicron strains. COVID-19 infection had a negative effect on the transplacental transfer ratio of SARS-CoV-2 antibodies. A booster dose during the second or third trimester is encouraged for the maximum transplacental transfer of humoral protection against COVID-19 for infants.

8 May 2023
Verified
Preprint
Open access
CCChia-Jung Chiang
Chia-Jung Chiang
WHWei-Lun Hsu
Wei-Lun Hsu
MSMeitsz Su
Meitsz Su
WKWen-Chien Ko
Wen-Chien Ko
KHKeng-Fu Hsu
Keng-Fu Hsu
PTPei-Yin Tsai
Pei-Yin Tsai
Objective To determine the optimal timing of SARS-CoV-2 vaccination during pregnancy by investigating the transplacental transfer of SARS-CoV-2 antibodies from maternal SARS-CoV-2 vaccination or infection. Design Prospective cohort study Setting Samples were collected between June 6, 2022 and September 20, 2022 in Taiwan. Sample Seventy-five maternal-cord pairs, including 38 pairs with a primary maternal SARS-CoV-2 infection by the Omicron variant (BA.2.3.7) and 37 pairs without maternal infection. Methods SARS-CoV-2 antibodies against the nucleocapsid (anti-N), receptor-binding domain of the spike protein (anti-S), and the neutralizing antibody (nAb) titers against different SARS-CoV-2 variants were measured for the maternal-cord pairs. The participants were categorized based on the timing of their last vaccination, including during the third (T3) and second trimesters (T2) and before/during the first trimester (T1). Comparison of anti-spike protein antibody and neutralizing antibody concentrations was analyzed using the Kruskal-Wallis test followed by a post-hoc Mann-Whitney U test. Main Outcome Measures Anti-S concentrations of maternal and cord serum among T1, T2, and T3 groups. Results Among participants without SARS-CoV-2 infection, the highest anti-S levels ( p value for anti-S levels in maternal and cord plasma were <0.001 and <0.001, respectively) and highest nAb potency against both the Wuhan and Omicron strains ( p value for nAb against Omicron strain were both <0.001 for maternal and cord plasma) were observed in maternal and cord plasma in the T3 group. Conclusions A booster vaccine dose during the third trimester can provide maximum transplacental protection against the Wuhan wild-type strain and Omicron variant. Pregnant women are encouraged to receive vaccinations during pregnancy, ideally in the third trimester, for the highest level of neonatal protection.

12 December 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
CTChun Han Tseng
Chun Han Tseng
CLChih-Wei Lin
Chih-Wei Lin
PTPei-Yin Tsai
Pei-Yin Tsai
MSMei-Tsz Su
Mei-Tsz Su
Objectives: We aim to study the relative viral load using salivary polymerase chain reaction among pregnant women treated with Paxlovid. Methods: Pregnant women with coronavirus disease 2019 were allocated to two groups: those receiving Paxlovid and those receiving no antiviral agents. We compared the nasopharyngeal and salivary relative viral loads and their changes in saliva specimens. Results: Among the thirty-seven pregnant women, seventeen received Paxlovid, and twenty received no antiviral agents. The viral cycle threshold value of saliva was significantly higher than that from nasopharynx, with a median ± interquartile range of 26.44 ± 7.68 versus 17.6 ± 9.6 in the Paxlovid group (p = 0.005). Following treatment, the median salivary viral load decreased by 13.40 cycle threshold values in the Paxlovid group (from a median of [Day 0 Ct] to [Day 4/5 Ct]), compared to a change of −1.59 cycle threshold values in the no-antiviral group (from a median of [Day 0 Ct] to [Day 4/5 Ct]) (p = 0.021). The detection rate of coronavirus disease 2019 using salivary polymerase chain reaction was 83.8% (31/37). Conclusions: This study showed that saliva is a useful diagnostic tool for coronavirus disease 2019 in pregnant women, and a significant decrease in the relative viral load of saliva was observed in those treated with Paxlovid.